Good news: a hitherto lethal disease can now be more or less cured.
Bad news: the disease is so rare that no one wants to commercialize the therapy.
Good news: regulatory structures can be fixed more esily than children's missing immune systems. But will we?
Gene therapy trial shows promise for treating ‘bubble boy’ syndrome. Now comes the hard part https://trib.al/aD3KuL7